s S217 de Chile, Santiago, Chile; 3Unidad de Trasplante, Instituto Nacional del Torax, Santiago, Chile. Purpose: Bridge-to-transplant long-term devices are commonly not affordable for our health system and usually they are not suitable for critically ill patients. Centrimag® may be an alternative for a one-step bridge-to-transplant surgical procedure. Methods: Retrospective review of 28 patients subjected to Centrimag® implantation. Twenty-three (82%) were male, mean age 42+13 years. Etiology of heart failure was ischemic in 13(46%), dilated cardiomyopathy in 8(29%), and other 7(25%).All were INTERMACS class I, 27(96%) had multiorgan failure, and in 26(93%) the indication was failure of medical management. Twelve (43%) had previous cardiac arrest with a mean arrest time of 21+17 min. Circulatory support was biventricular: 25(89%), univentricular 3(11%), and in 9(32%) an oxygenator was interposed until respiratory recovery. Results: Thirty-day post-implant survival was 79% (22 patients). Bridge-totransplant or recovery: 20 (71%) patients. Mean support time was 40 days, and 12(43%) were supported > 4 weeks. The longest support was 292 days. Eight (29%) died before been bridged. Post-implant complications: re-exploration for bleeding 10(36%), neurologic dysfunction 4(14%), pneumonia 10(36%), bacteremia 5(36%) and acute dialysis 8(29%). Kaplan Meier two-year survival: 62+10%. Mean follow-up time: 21 months with a total of 579 months. All alive patients were in NYHA functional class I with normal biventricular function. Conclusion: Centrimag® is useful to provide medium-term support for cardiogenic shock in a developing country. Support longer than 4 weeks is feasible. A bridge-to-transplant long-term device may not be needed in the setting of a waiting time less than 3 months.